A Comprehensive Long-term Retrospective Analysis of Silent Corticotrophic Adenomas vs Hormone-Negative Adenomas

被引:77
|
作者
Jahangiri, Arman [1 ,2 ]
Wagner, Jeffrey R. [3 ]
Pekmezci, Melike [4 ]
Hiniker, Anne [4 ]
Chang, Edward F. [3 ]
Kunwar, Sandeep [1 ,2 ]
Blevins, Lewis [1 ,2 ,5 ]
Aghi, Manish K. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, CCPD, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Neuropathol, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Div Endocrinol & Metab, San Francisco, CA 94143 USA
关键词
Adrenocorticotropic hormone; Cushing disease; Nonfunctioning; Pituitary tumors; Recurrence; Silent corticotrophic; CAVERNOUS SINUS INVASION; PITUITARY-ADENOMA; TUMORS; PROOPIOMELANOCORTIN; PRECURSOR;
D O I
10.1227/01.neu.0000429858.96652.1e
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Silent corticotrophic adenomas (SCAs) stain adrenocorticotropic hormone (ACTH) 1 without causing Cushing disease. SCAs are reportedly more aggressive, but information comes from small series. OBJECTIVE: To determine whether SCAs behave more aggressively than hormone-negative adenomas (HNAs), and characterize SCA ACTH production alterations. METHODS: SCAs (n = 75) and HNAs (n = 1726) diagnosed at our institution from 1990 to 2011 were retrospectively reviewed. RT-PCR was used to compare expression of ACTH-producing factors. RESULTS: SCA patients exhibited comparable sex and age as HNA patients (P = .7-.9). SCAs exhibited comparable size as HNAs (2.2 vs 2.0 cm, P = .2), with cavernous sinus invasion in 30% of SCAs vs 18% of HNAs (P = .03). SCA patients had higher mean pre-operative serum ACTH (46 vs 19 ng/L; P = .005; normal = 5-27 ng/L), but comparable serum cortisol (13 vs 12 mu g/dL; normal = 4-22 mu g/dL; P < .05) as HNA patients. SCAs were gross totally resected 59% of the time, vs 53% for HNAs (P = .8). Kaplan-Meier 3-year progression/recurrence rates were 34% for strongly ACTH-positive Type I SCAs, 10% for weakly ACTH-positive Type II SCAs, and 6% for HNAs (P < .001 SCA vs HNA; P < .001 Type I vs HNA; and P = .08 Type II vs HNA). Expression of ACTH precursor pro-opiomelanocortin was 900-fold elevated in SCAs and 1300-fold elevated in Cushing disease-causing adenomas (CDCAs) vs HNAs (P < .001). Transcription of PC1/3, which cleaves pro-opiomelanocortin into ACTH, was 30-fold higher in CDCAs than SCAs (P = .02). CONCLUSION: In the largest series to date, SCAs exhibited comparable size, but increased cavernous sinus invasion and progression/recurrence vs HNAs. SCAs exhibit deficient pro-opiomelanocortin to ACTH conversion. Close follow-up is warranted for SCAs.
引用
收藏
页码:8 / 17
页数:10
相关论文
共 50 条
  • [1] Silent corticogonadotroph adenomas: Clinical and cellular characteristics and long-term outcomes
    Cooper O.
    Ben-Shlomo A.
    Bonert V.
    Bannykh S.
    Mirocha J.
    Melmed S.
    Hormones and Cancer, 2010, 1 (2): : 80 - 92
  • [2] Treatment Strategies and Long-Term Outcomes in Silent Corticotroph Adenomas: A Single-Center Retrospective Study of 367 Cases
    He, Wenqiang
    Yao, Shun
    Yu, Yifei
    Chen, Zhengyuan
    Zhang, Qilin
    Qiao, Nidan
    Shen, Ming
    Shou, Xuefei
    Ma, Zengyi
    Wang, Yongfei
    NEUROSURGERY, 2025, 96 (03) : 611 - 621
  • [3] Silent corticotroph pituitary adenomas: clinical characteristics, long-term outcomes, and management of disease recurrence
    Strickland, Ben A.
    Shahrestani, Shane
    Briggs, Robert G.
    Jackanich, Anna
    Tavakol, Sherwin
    Hurth, Kyle
    Shiroishi, Mark S.
    Liu, Chia-Shang J.
    Carmichael, John D.
    Weiss, Martin
    Zada, Gabriel
    JOURNAL OF NEUROSURGERY, 2021, 135 (06) : 1706 - 1713
  • [4] Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity
    Erridge, Sara C.
    Conkey, David S.
    Stockton, Diane
    Strachan, Mark W. J.
    Statham, Patrick F. X.
    Whittle, Ian R.
    Grant, Robin
    Kerr, Gillian R.
    Gregor, Anna
    RADIOTHERAPY AND ONCOLOGY, 2009, 93 (03) : 597 - 601
  • [5] Radiotherapy for pituitary adenomas: long-term outcome and complications
    Rim, Chai Hong
    Yang, Dae Sik
    Park, Young Je
    Yoon, Won Sup
    Lee, Jung Ae
    Kim, Chul Yong
    RADIATION ONCOLOGY JOURNAL, 2011, 29 (03): : 156 - 163
  • [6] Long-Term Outcomes of Endoscopic Papillectomy for Ampullary Adenomas
    Sahar, Nadav
    Krishnamoorthi, Rajesh
    Kozarek, Richard A.
    Gluck, Michael
    Larsen, Michael
    Ross, Andrew S.
    Irani, Shayan
    DIGESTIVE DISEASES AND SCIENCES, 2020, 65 (01) : 260 - 268
  • [7] Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas
    Chopinet, Sophie
    Cauchy, Francois
    Hobeika, Christian
    Beaufrere, Aurelie
    Pote, Nicolas
    Farges, Olivier
    Dokmak, Safi
    Bouattour, Mohamed
    Ronot, Maxime
    Vilgrain, Valerie
    Paradis, Valerie
    Soubrane, Olivier
    JHEP REPORTS, 2021, 3 (04)
  • [8] Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up
    Vernuccio, Federica
    Ronot, Maxime
    Burgio, Marco Dioguardi
    Cauchy, Francois
    Choudhury, Kingshuk R.
    Dokmak, Safi
    Soubrane, Olivier
    Valla, Dominique
    Zucman-Rossi, Jessica
    Paradis, Valerie
    Vilgrain, Valerie
    RADIOLOGY, 2020, 295 (02) : 361 - 372
  • [9] Long-Term Outcomes After CyberKnife Radiosurgery for Nonfunctioning Pituitary Adenomas
    Wei, Nathan
    Gunawan, Kevin
    Tsai, Chiao-Ling
    Yang, Shih-Hung
    Hsu, Feng-Ming
    Lai, Dar-Ming
    Xiao, Furen
    NEUROSURGERY, 2025, 96 (04) : 892 - 900
  • [10] Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study
    Sumislawski, Piotr
    Huckhagel, Torge
    Krajewski, Kara Leigh
    Aberle, Jens
    Saeger, Wolfgang
    Flitsch, Joerg
    Rotermund, Roman
    SCIENTIFIC REPORTS, 2023, 13 (01)